Advertising Zone 10

NLS

January 15, 2017

[aas_zone zone_id=”8010″]

Published: January 15, 2017

Lilly to acquire Orna Therapeutics to advance cell therapies

Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient’s own body to generate cell therapies that can treat underlying disease.

Global report – February 9, 2026

Innovent and Lilly in strategic collaboration

Innovent Biologics has announced a strategic collaboration with Eli Lilly and Company (“Lilly”) to advance novel medicines in oncology and immunology.

Science News – February 9, 2026

Nordic registers reveal COVID‑19’s impact on cancer survival

A 2026 population‑based cohort study covering Denmark, Finland, Iceland, Norway and Sweden analysed 1‑year relative survival and excess mortality in cancer patients diagnosed during March–December 2020 versus expectations from 2011–2019.

Biotech Business – February 9, 2026

Carl Bennet invests SEK 45 million in Medivir

Medivir has completed a directed share issue of SEK 45 million (before issue costs) to Carl Bennet AB, issuing 90 million new shares at SEK 0.50 per share—a 19 percent premium to the closing price on February 5, 2026.